The reported profit is entirely from a non-recurring catch-up adjustment; the underlying operating loss (ex-catch-up) was approximately $15.9M. Monitor the 10-Q for details on the restructuring and the timeline for the I&I and EP300 programs, as these are the key value drivers.
FHTX drugs
FHTX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $2.04entry
- T+1 · 7d ago −6.86%α −6.49% · $1.90
- T+5 · 20h ago −12.25%α −10.56% · $1.79
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Foghorn Therapeutics reported Q3 2026 net income of $58.2M, driven by a $74.1M cumulative catch-up adjustment in collaboration revenue from the decision to not advance two partnered programs. The company has $156.2M in cash with runway into H2 2029, but the core business remains pre-revenue and the reported profit is non-recurring. Consensus estimates were not met on an operating basis.
Key Financial Metrics
Key Facts
- Net income of $58.2M vs net loss of $15.8M in Q3 2025, driven by $74.1M cumulative catch-up adjustment in collaboration revenue
- Collaboration revenue of $83.5M vs $8.2M in Q3 2025, primarily from the catch-up adjustment
- Cash, cash equivalents and marketable securities of $156.2M, providing runway into H2 2029
- R&D expenses decreased to $18.8M from $20.0M; G&A expenses decreased to $5.8M from $6.7M
- Restructuring costs of $2.3M incurred in Q3 2026
- Preclinical programs advancing: oral I&I program targeting IND in 2027, Selective EP300 degrader targeting IND in 2027
- Diluted EPS of $0.80 vs consensus estimate of ($0.25), but this is GAAP profit from non-recurring revenue
Financial Impact
Net income of $58.2M vs consensus loss of ~$15.8M; collaboration revenue of $83.5M vs consensus $7.1M, but $74.1M is a one-time catch-up adjustment
Risk Factors
- Reported profitability is non-recurring; core operating loss continues
- Preclinical programs have not yet entered clinical trials; no near-term revenue catalysts
- Restructuring costs and program discontinuation signal pipeline prioritization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398284 |
Track record
9 reports on FHTX
1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +31.85% at T+5 after the Oct 1, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $1.81 Now $1.79 −0.83% settles Dec 15
- Nov 9, 20267d ago Press Release Neutral 4/10 Viewing Entry $2.04 Now $1.79 −12.25% settles Dec 8
- Oct 5, 20266w ago 3 Neutral 2/10 Entry $1.97 to $2.12 Now $1.79 −9.14% ▲ +7.36% +10.26% vs SPY
- Oct 5, 20266w ago SC 13G/A Neutral 4/10 Entry $1.97 to $2.13 Now $1.79 −9.14% ▲ +8.12% +11.30% vs SPY
- Oct 1, 20266w ago 8-K Bearish 7/10 Entry $2.92 to $2.09 Now $1.79 +38.70% ▲ +28.42% +29.13% vs SPY
- Aug 6, 202614w ago 8-K Mixed 5/10 Entry $5.57 to $4.87 Now $1.79 −67.86% ▼ −12.57% −13.17% vs SPY
- May 7, 202627w ago 8-K Neutral 3/10 Entry $4.20 to $3.64 Now $1.79 −57.38% ▼ −13.33% −16.47% vs SPY
- Apr 21, 202629w ago Press Release Bullish 7/10 Entry $5.39 to $3.60 Now $1.79 −66.79% ▼ −33.21% −36.38% vs SPY
- Apr 21, 202629w ago 8-K Bullish 7/10 Entry $5.39 to $3.60 Now $1.79 −66.79% ▼ −33.21% −36.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers